One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euros, and ...

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that hasn’t stopped it making a strong start in the US market. Zolgensma (onasemnogene ...

At ASCO 2025 in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Dr Jason Williams, director of interventional ...

Uniting 100+ precision medicine leaders from biopharma, diagnostic development, regulation, and healthcare institutes, the ...

In its second-quarter financial filing, Iovance said it was planning to shed 19% of its workforce of more than 630 in order ...

We assume that what worked in the 1950s still works now. We assume that more budget is the only answer. Yet, AI can help in transformative ways if adopted at scale. If AI were scaled across the NHS to ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The smartphone-based CT-155 app, co-developed by Click Therapeutics and Boehringer Ingelheim, was able to help users achieve ...